These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23679896)

  • 1. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
    Papp KA; Sundaram M; Bao Y; Williams DA; Gu Y; Signorovitch JE; Wang Y; Valdes JM; Mulani PM
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):790-8. PubMed ID: 23679896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB; Yu AP; Signorovitch J; Xie J; Tsaneva M; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
    J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
    Reich K; Langley RG; Papp KA; Ortonne JP; Unnebrink K; Kaul M; Valdes JM
    N Engl J Med; 2011 Oct; 365(17):1586-96. PubMed ID: 22029980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
    Gordon KB; Langley RG; Gottlieb AB; Papp KA; Krueger GG; Strober BE; Williams DA; Gu Y; Valdes JM
    J Invest Dermatol; 2012 Feb; 132(2):304-14. PubMed ID: 22011907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE; Sobell JM; Duffin KC; Bao Y; Guérin A; Yang H; Goldblum O; Okun MM; Mulani PM
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
    Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Gottlieb AB; Leonardi C; Kerdel F; Mehlis S; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):652-60. PubMed ID: 21574983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
    Reich K; Schenkel B; Zhao N; Szapary P; Augustin M; Bourcier M; Guenther L; Langley RG
    J Dermatolog Treat; 2011 Dec; 22(6):337-47. PubMed ID: 21034290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.